CJC-1295 + Ipamorelin Peptide

Description

CJC-1295 + Ipamorelin at a glance. CJC-1295 (no DAC) + Ipamorelin 5 mg + 5 mg, a lyophilised powder for laboratory research use, costs €79.90 at Pepspan. The current lot, PEP-CJCIPA-2608-01, was tested by Janoshik Analytical for content per vial (CJC-1295 4.89 mg + Ipamorelin 4.81 mg) — verify the report. Ships from Europe with EU delivery in 2–5 days; free shipping on orders over €50. Pay by PayPal, SEPA bank transfer (−5%) or crypto (−15%).

CJC-1295 and Ipamorelin represent two distinct classes of growth hormone secretagogue peptides that, when combined, create a synergistic research model for studying the hypothalamic-pituitary growth hormone axis. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), a 29-amino-acid peptide modified with a Drug Affinity Complex (DAC) that extends its biological half-life from minutes to several days. Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that acts on the ghrelin receptor (GHS-R1a) to stimulate pituitary somatotrophs through a mechanism independent of GHRH signaling.

The pharmacological rationale for combining these two peptides centers on their complementary receptor targets. CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, initiating a cAMP-dependent signaling cascade that primes these cells for growth hormone (GH) synthesis and release. Ipamorelin acts on the distinct GHS-R1a receptor, amplifying the GH release signal through a separate intracellular pathway involving phospholipase C and protein kinase C. Research data indicates that co-administration produces a significantly greater GH pulse amplitude than either peptide alone, a phenomenon well-documented in secretagogue literature as synergistic potentiation.

A critical advantage of Ipamorelin over earlier-generation GHRPs such as GHRP-6 and GHRP-2 is its selectivity profile. In preclinical studies, Ipamorelin has demonstrated minimal effects on cortisol, prolactin, and aldosterone levels at GH-stimulating concentrations, making it a cleaner research tool for isolating GH-specific effects. This selectivity reduces confounding variables in experimental designs focused on the somatotropic axis. When paired with the sustained GHRH-receptor activation provided by CJC-1295, the combination enables researchers to study prolonged, pulsatile GH release patterns that more closely mimic physiological secretion dynamics.

Body composition studies in animal models have shown that sustained elevation of GH through this dual-pathway approach is associated with measurable changes in lean mass accretion and adipose tissue metabolism. The pulsatile nature of GH release induced by this combination, rather than continuous elevation, has been identified as a key factor in maintaining receptor sensitivity and avoiding desensitization artifacts that can complicate long-term research protocols. Additionally, IGF-1 levels, the primary mediator of many GH effects, show dose-dependent increases in response to combined CJC-1295 and Ipamorelin treatment in rodent models.

This product is supplied as a co-lyophilized powder containing 5mg of CJC-1295 and 5mg of Ipamorelin in a single vial. Both components exceed 98% purity as verified by independent HPLC analysis. Reconstitute with bacteriostatic water and use according to your institutional research protocols.

EU Shipping: Ships from the EU warehouse. Free shipping on orders over €50. No customs delays — intra-EU shipment. Tracked via Spring GDS / DHL EU Connect. Janoshik COA available per batch on request.

Reconstitution & Storage

The CJC-1295 + Ipamorelin 10mg co-lyophilized vial is supplied for reconstitution with bacteriostatic water (0.9% benzyl alcohol); in the laboratory this is done under aseptic conditions — swirl gently, do not shake, since vigorous agitation can fragment the longer CJC-1295 peptide chain.

• Expected appearance: Clear, colorless solution with no particulates.
• Post-reconstitution stability: Store at 2-8°C protected from light. Use within 21 days; discard if solution becomes cloudy or develops particulates.

Stability & Half-Life Data

• CJC-1295 (Modified GRF 1-29) plasma half-life: Approximately 30 minutes following subcutaneous administration in rodent pharmacokinetic studies. This is the version without DAC (Drug Affinity Complex) — the DAC-bound long-acting form, which is a different compound, has a half-life of approximately 8 days.
• Ipamorelin plasma half-life: Approximately 2 hours following subcutaneous administration. Clearance occurs primarily via enzymatic degradation by serum and tissue peptidases.
• Lyophilized stability: Up to 24 months when stored at -20°C in a sealed vial protected from light and moisture. Up to 4 weeks at 2-8°C without measurable purity loss.
• Reconstituted stability: 21 days at 2-8°C in low-protein-binding polypropylene containers, protected from light. Ipamorelin is the rate-limiting component for degradation in solution.
• Thermal stability: Lyophilized form is stable up to 40°C for short transport excursions. Avoid sustained temperatures above 25°C.
• Freeze-thaw: Avoid repeated freeze-thaw cycles of reconstituted solution. Aliquot into single-use volumes before freezing if long-term storage is required.
• Synergy timing: Because the two peptides have different half-lives (30 min vs 2h), co-administration produces a sustained GH-release window during the period of overlapping receptor activation, peaking 15-30 minutes post-injection.

Composition

• Component 1: CJC-1295 (Modified GRF 1-29)
• CJC-1295 Molecular Formula: C152H252N44O42
• CJC-1295 Molecular Weight: 3367.97 g/mol
• Component 2: Ipamorelin
• Ipamorelin Molecular Formula: C38H49N9O5
• Ipamorelin Molecular Weight: 711.85 g/mol
• Purity: >98% each component (HPLC)
• Appearance: White lyophilized powder
• Quantity: 5mg + 5mg per vial

Storage

• Store lyophilized peptide at -20C for long-term storage (up to 24 months).
• For short-term storage (up to 4 weeks), refrigerate at 2-8C.
• After reconstitution, store at 2-8C and use within 21 days.
• Avoid repeated freeze-thaw cycles.
• Protect from light and moisture at all times.

Certificate of Analysis

Yes. Each lot of CJC-1295 + Ipamorelin is analysed independently by Janoshik Analytical (Prague, Czech Republic). The current lot PEP-CJCIPA-2608-01 was analysed on 7 September 2026: CJC-1295 (mod GRF 1-29) 4.89 mg and Ipamorelin 4.81 mg per vial. The full report and the laboratory's verification link are at /l/CJCIPA2608. Reports are lot-specific, not generic.

Current batch PEP-CJCIPA-2608-01: analysed 2026-09 · report published

Every batch of CJC-1295 + Ipamorelin sold by Pepspan is independently tested by Janoshik Analytical (Prague, Czech Republic). HPLC purity and the actual content per vial are measured for each shipment. Reports are batch-specific — not generic.

Research Disclaimer

This product is intended for laboratory research use only. It is not a drug, food, cosmetic, or dietary supplement. CJC-1295 and Ipamorelin are not approved for human or veterinary use by any regulatory agency. They must not be administered to humans or animals outside of approved clinical trials. By purchasing this product, you confirm that you are a qualified researcher and that this product will be used exclusively for legitimate scientific research purposes. Pepspan assumes no liability for any misuse of this product. All handling must comply with local regulations and institutional safety protocols.

Further Research Resources

Additional research articles, comparison guides, and laboratory protocols related to this peptide:

• CJC-1295 + Ipamorelin growth-hormone research
• Bacteriostatic water complete reconstitution guide
• How to reconstitute lyophilized peptides